4.6 Article

Differential Regulation of Chemokines by IL-17 in Colonic Epithelial Cells

期刊

JOURNAL OF IMMUNOLOGY
卷 181, 期 9, 页码 6536-6545

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.181.9.6536

关键词

-

资金

  1. Crohn's and Colitis Foundation of America
  2. National Institutes of Health [R01-GM066151, R01-NS55997]

向作者/读者索取更多资源

The IL-23/IL-17 pathway plays an important role in chronic inflammatory diseases, including inflammatory bowel disease. In inflammatory bowel disease, intestinal epithelial cells are an important source of chemokines that recruit inflammatory cells. We examined the effect of IL-17 on chemokine expression of HT-29 colonic epithelial cells. IL-17 strongly repressed TNF-alpha-stimulated expression of CXCL10, CXCL11, and CCL5, but synergized with TNF-alpha for induction of CXCL8, CXCL1, and CCL20 mRNAs. For CXCL10, IL-17 strongly inhibited promoter activity but had no effect on mRNA stability. In contrast, for CXCL8, IL-17 slightly decreased promoter activity but stabilized its normally unstable mRNA, leading to a net increase in steady-state mRNA abundance. IL-17 synergized with TNF-alpha in transactivating the epidermal growth factor receptor (EGFR) and in activating ERK and p38 MAPK. The p38 and ERK pathway inhibitors SB203580 and U0126 reversed the repressive effect of IL-17 on CXCL10 mRNA abundance and promoter activity and also reversed the inductive effect of IL-17 on CXCL8 mRNA, indicating that MAPK signaling mediates both the transcriptional repression of CXCL10 and the stabilization of CXCL8 mRNA by IL-17. The EGFR kinase inhibitor AG1478 partially reversed the effects of IL-17 on CXCL8 and CXCL10 mRNA, demonstrating a role for EGFR in downstream IL-17 signaling. The overall results indicate a positive effect of IL-17 on chemokines that recruit neutrophils (CXCL8 and CXCL1), and Th17 cells (CCL20). In contrast, IL-17 represses expression of CXCL10, CXCL11, and CCR5, three chemokines that selectively recruit Th1 but not other effector T cells. The Journal of Immunology, 2008, 181: 6536-6545.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis

Bao Ying Chen, Jessica R. Salas, Alyssa O. Trias, Arely Perez Rodriguez, Jonathan E. Tsang, Miriam Guemes, Thuc M. Le, Zoran Galic, H. Michael Shepard, Lawrence Steinman, David A. Nathanson, Johannes Czernin, Owen N. Witte, Caius G. Radu, Kenneth A. Schultz, Peter M. Clark

Summary: Research on multiple sclerosis and autoimmune diseases has found that targeting deoxycytidine kinase (dCK) can limit the progression of symptoms, and dCK activity is essential for activation-induced proliferation in specific lymphocytes.

IMMUNOLOGY (2023)

Article Medicine, General & Internal

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Lawrence Steinman, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, DeRen Huang, Krzysztof Selmaj, Daniel Wynn, Gary Cutter, Koby Mok, Yanzhi Hsu, Yihuan Xu, Michael S. Weiss, Jenna A. Bosco, Sean A. Power, Lily Lee, Hari P. Miskin, Bruce A. C. Cree

Summary: Ublituximab shows promise as a treatment for relapsing multiple sclerosis, reducing relapse rates and brain lesions compared to teriflunomide over a 96-week period. However, it does not significantly decrease the risk of disability worsening.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Clinical Neurology

Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder From the National Multiple Sclerosis Society Case Conference Proceedings

Carolyn Goldschmidt, Steven L. Galetta, Robert P. Lisak, Laura J. Balcer, Andrew Hellman, Michael K. Racke, Amy E. Lovett-Racke, Roberto Cruz, Matthew S. Parsons, Neda Sattarnezhad, Lawrence Steinman, Scott S. Zamvil, Elliot M. Frohman, Teresa C. Frohman

Summary: A woman was diagnosed with relapsing-remitting multiple sclerosis (MS) as a teenager and later developed neuromyelitis optica spectrum disorder in her sixties. This case highlights the importance of reconsidering the working diagnosis when faced with evidence of a distinctly different disorder.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Review Immunology

Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease

Lawrence Steinman, Roberto Patarca, William Haseltine

Summary: Twenty years ago, a tribute was published in this journal to celebrate the 70th anniversary of an animal model known as experimental autoimmune encephalomyelitis (EAE). Recent research has helped explain how Epstein-Barr virus triggers multiple sclerosis through molecular mimicry. These observations bring us back to Rivers' first paper on EAE, published 90 years ago, and show the continued importance of this animal model in understanding disease mechanisms.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Article Multidisciplinary Sciences

T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity

Sharon A. Sagan, Zahra Moinfar, Carson E. Moseley, Ravi Dandekar, Collin M. Spencer, Alan S. Verkman, Ole Petter Ottersen, Raymond A. Sobel, John Sidney, Alessandro Sette, Mark S. Anderson, Lawrence Steinman, Michael R. Wilson, Joseph J. Sabatino, Scott S. Zamvil

Summary: This study investigates the role of AQP4-specific Th17 cells in the pathogenesis of neuromyelitis optica (NMO). The research shows that AQP4-specific T cells have a high affinity for binding to MHC II, and their clonal expansion is observed in AQP4-deficient mice. Thymic negative selection alone does not account for the tolerance to AQP4 in wild-type (WT) mice. AQP4-specific Th17 cells can cause paralysis followed by recovery, associated with apoptosis of donor T cells. However, these cells can persist and cause persistent paralysis in mice deficient in both T and B cells or lacking T cells only. In contrast, MOG-specific T cells survive and cause sustained disease in WT mice.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Multidisciplinary Sciences

Elevated α5 integrin expression on myeloid cells in motor areas in amyotrophic lateral sclerosis is a therapeutic target

Aude Chiot, Shanu F. Roemer, Lisa Ryner, Alina Bogachuk, Katie Emberley, Dillon Brownell, Gisselle A. Jimenez, Michael Leviten, Randall Woltjer, Dennis W. Dickson, Lawrence Steinman, Bahareh Ajami

Summary: This study found that alpha 5 integrin is prominently expressed in motor pathways and perivascular zones associated with the blood-brain barrier in ALS patients and mouse models. Treatment with an antibody against alpha 5 integrin improved survival and motor function in the mouse model.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Review Immunology

Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials

Tobias Lanz, William H. Robinson, Peggy P. Ho, Lawrence Steinman

Summary: We propose studying the molecular mechanisms underlying the clonal antibody response in cerebrospinal fluid and exploring therapeutic approaches to block EBV-triggered multiple sclerosis. These include antiviral clinical trials, development of nucleic acid-based vaccines, cellular adoptive therapy, and vaccines to EBV. These topics are not exhaustive, but our medical science community has the tools to tackle EBV-triggered MS and potentially eradicate the disease, as we have done with poliomyelitis.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2023)

Meeting Abstract Clinical Neurology

Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial

K. W. Selmaj, L. Steinman, G. Comi, A. Bar-Or, H. P. Hartung, X. Montalban, E. K. Havrdova, J. K. Sheffield, A. Thorpe, J. V. Riolo, A. Krakovich, C. Y. Cheng, L. Kappos, J. A. Cohen, B. A. C. Cree

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis

Enrique Alvarez, Lawrence Steinman, Hans-Peter Hartung, Edward Fox, Peiqing Qian, Sibyl Wray, Derrick Robertson, Koby Mok, Christopher A. Garner, Bruce Cree

NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies

Lawrence Steinman, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, Deren Huang, Krzysztof Selmaj, Daniel Wynn, Jenna Bosco, Koby Mok, Christopher A. Garner, Bruce Cree

NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study

K. W. Selmaj, J. A. Cohen, L. Steinman, G. Comi, A. Bar-Or, H. Hartung, X. Montalban, L. Kappos, J. K. Sheffield, A. Krakovich, C. Cheng, J. Riolo, D. Silva, B. A. Cree

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

Long-term Efficacy of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis in Two Phase 3 Trials and an Open-label Extension Trial

B. A. Cree, K. Selmaj, L. Steinman, G. Comi, A. Bar-Or, D. L. Arnold, H. Hartung, X. Montalban, E. K. Havrdova, J. K. Sheffield, C. Cheng, J. V. Riolo, D. Silva, L. Kappos, J. A. Cohen

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

The B Cell Repertoire in Multiple Sclerosis Reveals Molecular Mimicry between EBV EBNA1 and GlialCAM

T. V. Lanz, R. C. Brewer, P. P. Ho, L. Steinman, W. H. Robinson

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

Correlations between early MRI parameters and long-term clinical outcomes in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis

D. L. Arnold, L. Freeman, H. -P. Hartung, X. Xavier Montalban, J. A. Cohen, A. Bar-Or, L. Steinman, J. DeLuca, C. -Y. Cheng, J. V. Riolo, D. Silva, C. Pachai, B. A. C. Cree

MULTIPLE SCLEROSIS JOURNAL (2022)

Meeting Abstract Clinical Neurology

COVID-19 infections and vaccinations among patients receiving ozanimod in the daybreak open-label extension trial

B. A. Cree, K. W. Selmaj, L. Steinman, G. Comi, A. Bar-Or, D. L. Arnold, H. -P. Hartung, X. Montalban, K. Havrdova, H. Desai, J. K. Sheffield, N. Minton, C. -Y. Cheng, D. Silva, L. Kappos, J. A. Cohen

MULTIPLE SCLEROSIS JOURNAL (2022)

暂无数据